Oncology

Download Brochure


Oncology

Cancer known medically as a malignant neoplasm, is a broad group of various diseases, all involving unregulated cell growth. In cancer, cells divide and grow uncontrollably, forming malignant tumours, and invade nearby parts of the body. The cancer may also spread to more distant parts of the body. There are over 200 different known cancers that afflict humans. Cancer is the subject of widespread fear and taboos. There is a deep belief that cancer is necessarily a difficult and usually deadly disease.

Shilpa offers a comprehensive, high-quality portfolio and a dynamic pipeline of oncology drugs, which are beyond standard generics. We have a broad portfolio of 25 + products and a robust pipeline that addresses the needs of cancer treatment. By further growing our portfolio and strengthening our global presence, Shilpa will ensure that patients worldwide have greater access to a comprehensive range of these vital quality medicines at an affordable cost. We are proud to assert that the field of Oncology is one of our core competencies and we offer a comprehensive range of APIs and Finished Dosage Forms in this segment.

For more information on Shilpa‘s pipeline/products to treat cancer, Please find below Oncology product list.

Oncology API’s

Oncology API Tech Pack DMF Status
Open Part US EU TPD PMDA TGA EDQM KFDA GCC Medsafe DMF Number
Anastrozole                     DMF Available
Axitinib                     DMF Available
Azacitidine                   USDMF#27487
Abiraterone Acetate                      
Bendamustine HCL Monohydrate                 USDMF#25222
Bicalutamide               USDMF#24690
Bortezomib               USDMF#24944
Busulphan               USDMF#25491,
R0-CEP 2011-339-Rev 01
Cabazitaxel Amorphous                      
Capecitabine         USDMF#24689
Carboplatin                    
Cladribine                      
Clofarabine                     DMF Available
Cyclophosphamide Monohydrate                      
Cytarabine                      
Dasatinib                      
Decitabine                   USDMF#27488
Docetaxel                    
Erlotinib HCL                   USDMF#29124
Enzalutamide                      
Gemcitabine HCl     USDMF#24136,
R1-CEP 2006-222
Gefitinib                      
Hydroxy Urea                      
Imatinib Mesylate                   USDMF#27927
Irinotecan HCl Trihydrate         USDMF#23562
Lenalidomide                      
Letrozole                   USDMF#27489,
R0-CEP 2013-321-Rev 00
Melphalan HCL                     USDMF#28930
Oxaliplatin       USDMF#23563,
R1-CEP 2006-201
Paclitaxel                    
Pazopanib                      
Pemetrexed Disodium Hemipentahydrate                 USDMF#25102
Pemetrexed DiPotassium Nonahydrate                     DMF Available
Regorafinib                      
Sorafenib                      
Sunitinib                      
Temozolomide         USDMF#23479
Thalidomide                    
TopotecanHCl                      
Vismodegib                      
Zoledronic acid                   USDMF#25905
5- Fluoro Uracil                      

Under Development-Oncology API’s

PRODUCTS UNDER DEVELOPMENT (Oncology)
Bosutinib Crizotinib
Lapatinib Ditosylate Nilotinib
Vemurafenib Afatinib
Carfilzomib Ibrutinib
Mecitentan Vismodegib
Nintedanib Pomalidomide

* PRODUCTS UNDER VALID PATENTS ARE NOT OFFERED FOR COMMERCIAL OPERATIONS:
ONLY R&D QUANTITIES ARE OFFERED.

For Enquiries, please contact

Shilpa Medicare Limited

10/80, Rajendra Gunj, Raichur – 584 102 (India)
Tel: +91-8532-235006, Fax: +91-8532-235876
eMail: info@vbshilpa.com, vishnu@vbshilpa.com